Wang Qiao-Xuan, Qu Chun-Hua, Gao Yuan-Hong, Ding Pei-Rong, Yun Jing-Ping, Xie Dan, Cai Mu-Yan
Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, China.
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Exp Hematol Oncol. 2021 Jan 4;10(1):2. doi: 10.1186/s40164-020-00193-z.
The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicting the subset in this group that will benefit from PD-1 blockade remains a challenge. In this study, we aimed to investigate the relationship between the degree of microsatellite instability and the responses to anti-PD-1 immunotherapy. 33 patients with colorectal adenocarcinoma who had a known MSI status and received anti-PD-1 immunotherapy were included. PCR results for MSI of the whole cohort were collected and treatment response was evaluated. Our data indicated that objective response rate (ORR) in instability-high group (instability loci ≥ 3) was significantly higher than ORR in instability-intermediate group (13/16 versus 6/17, P = 0.008). Besides, patients in instability-high group had significant longer progression-free survival (log-rank test, P = 0.004), and a significant increase in T lymphocyte infiltration and cytolytic activity in tumors. Future study might implement the intensity of microsatellite instability for more delicate selection for anti-PD-1 therapy in patient with dMMR/MSI-H tumors.
程序性细胞死亡蛋白1抑制剂(PD-1)的研发为治疗DNA错配修复系统缺陷或微卫星不稳定(dMMR/MSI)的肿瘤带来了曙光。然而,预测该组中能从PD-1阻断治疗中获益的亚组仍然是一项挑战。在本研究中,我们旨在探讨微卫星不稳定程度与抗PD-1免疫治疗反应之间的关系。纳入了33例已知微卫星不稳定状态且接受抗PD-1免疫治疗的结肠腺癌患者。收集了整个队列微卫星不稳定的PCR结果并评估治疗反应。我们的数据表明,高度不稳定组(不稳定位点≥3)的客观缓解率(ORR)显著高于中度不稳定组(13/16对6/17,P = 0.008)。此外,高度不稳定组患者的无进展生存期显著更长(对数秩检验,P = 0.004),且肿瘤中的T淋巴细胞浸润和细胞溶解活性显著增加。未来的研究可能会利用微卫星不稳定的强度,为dMMR/MSI-H肿瘤患者更精准地选择抗PD-1治疗。